Immutep Limited American Depositary Shares (IMMP)

Immutep will present data from its EFTISARC-NEO Phase II trial evaluating eftilagimod alpha in combination with pembrolizumab and radiotherapy for soft tissue sarcoma at the CTOS 2025 Annual Meeting in November.

Immutep Ltd (ASX: IMM) is surging after receiving positive feedback from the FDA for its planned Phase 3 trial of its eftilagimod alfa compound in combination with Merck & Co's Keytruda for treating non-small cell lung cancer. This is a critical milestone for the company.

Immutep announced positive results from cohort B of the late-stage TACTI-003 study, evaluating the combination of its pipeline candidate eftilagimod alfa and Merck's Keytruda as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma. The combination therapy showed promising efficacy and safety data, strengthening the evidence that efti's novel mechanism of action significantly boosts the immune system.

Immutep's lead cancer drug eftilagimod alfa (efti) in combination with Merck's Keytruda showed promising results in a Phase 2b trial for recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression, leading to a surge in Immutep's stock price.

5 Penny Stocks To Watch Under $5 Before Next Week. The post Best Penny Stocks To Buy Now? 5 to Watch Under $5 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.